Recce Pharmaceuticals Ltd
ASX:RCE

Watchlist Manager
Recce Pharmaceuticals Ltd Logo
Recce Pharmaceuticals Ltd
ASX:RCE
Watchlist
Price: 0.455 AUD -5.21% Market Closed
Market Cap: 105.5m AUD
Have any thoughts about
Recce Pharmaceuticals Ltd?
Write Note

Relative Value

The Relative Value of one RCE stock under the Base Case scenario is 0.074 AUD. Compared to the current market price of 0.455 AUD, Recce Pharmaceuticals Ltd is Overvalued by 84%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

RCE Relative Value
Base Case
0.074 AUD
Overvaluation 84%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
87
vs Industry
11
Median 3Y
40.3
Median 5Y
65
Industry
2.6
Forward
10.9
vs History
vs Industry
Median 3Y
-10.9
Median 5Y
-16.4
Industry
22.1
Forward
-6.4
vs History
11
vs Industry
17
Median 3Y
-10.3
Median 5Y
-22.9
Industry
16.5
vs History
11
vs Industry
13
Median 3Y
-10.2
Median 5Y
-21.5
Industry
24
vs History
vs Industry
0
Median 3Y
15
Median 5Y
14.6
Industry
2.1
vs History
87
vs Industry
11
Median 3Y
39.8
Median 5Y
61.3
Industry
2.7
Forward
10.5
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.3
vs History
vs Industry
Median 3Y
-11
Median 5Y
-14.9
Industry
13.7
Forward
-7.9
vs History
vs Industry
Median 3Y
-11
Median 5Y
-14.9
Industry
17
Forward
-7.7
vs History
11
vs Industry
19
Median 3Y
-10.1
Median 5Y
-21
Industry
15.5
vs History
11
vs Industry
17
Median 3Y
-10.1
Median 5Y
-20.8
Industry
19.6
vs History
vs Industry
0
Median 3Y
257.3
Median 5Y
343
Industry
2

Multiples Across Competitors

RCE Competitors Multiples
Recce Pharmaceuticals Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Recce Pharmaceuticals Ltd
ASX:RCE
105.5m AUD 20.1 -6 -6 -6
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
739.6B USD 18.1 88.4 47.5 53
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.4T DKK 12.6 35.9 25 28.5
US
Johnson & Johnson
NYSE:JNJ
352.5B USD 4 24 11.6 15.1
US
Merck & Co Inc
NYSE:MRK
253.4B USD 4 20.9 10.5 12.6
CH
Roche Holding AG
SIX:ROG
205.5B CHF 3.5 17.9 10.1 11.9
UK
AstraZeneca PLC
LSE:AZN
162.9B GBP 4.2 32.1 169.6 254.2
CH
Novartis AG
SIX:NOVN
173.6B CHF 3.9 11 9.6 13.3
US
Pfizer Inc
NYSE:PFE
149.8B USD 2.5 35.2 10.5 15.9
P/S Multiple
Revenue Growth P/S to Growth
AU
Recce Pharmaceuticals Ltd
ASX:RCE
Average P/S: 382 944
20.1
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
4 211 733
22%
194 879.4
US
Eli Lilly and Co
NYSE:LLY
18.1
109%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
578.3
29%
19.9
DK
Novo Nordisk A/S
CSE:NOVO B
12.6
77%
0.2
US
Johnson & Johnson
NYSE:JNJ
4
12%
0.3
US
Merck & Co Inc
NYSE:MRK
4
20%
0.2
CH
Roche Holding AG
SIX:ROG
3.5
15%
0.2
UK
AstraZeneca PLC
LSE:AZN
4.2
35%
0.1
CH
Novartis AG
SIX:NOVN
3.9
17%
0.2
US
Pfizer Inc
NYSE:PFE
2.5
10%
0.2
P/E Multiple
Earnings Growth P/E to Growth
AU
Recce Pharmaceuticals Ltd
ASX:RCE
Average P/E: 33.2
Negative Multiple: -6
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
88.4
451%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
35.9
86%
0.4
US
Johnson & Johnson
NYSE:JNJ
24
-22%
N/A
US
Merck & Co Inc
NYSE:MRK
20.9
7 314%
0
CH
Roche Holding AG
SIX:ROG
17.9
54%
0.3
UK
AstraZeneca PLC
LSE:AZN
32.1
177%
0.2
CH
Novartis AG
SIX:NOVN
11
31%
0.4
US
Pfizer Inc
NYSE:PFE
35.2
733%
0
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
Recce Pharmaceuticals Ltd
ASX:RCE
Average EV/EBITDA: 460.1
Negative Multiple: -6
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
47.5
195%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
151%
25.5
DK
Novo Nordisk A/S
CSE:NOVO B
25
84%
0.3
US
Johnson & Johnson
NYSE:JNJ
11.6
14%
0.8
US
Merck & Co Inc
NYSE:MRK
10.5
331%
0
CH
Roche Holding AG
SIX:ROG
10.1
23%
0.4
UK
AstraZeneca PLC
LSE:AZN
169.6
64%
2.7
CH
Novartis AG
SIX:NOVN
9.6
8%
1.2
US
Pfizer Inc
NYSE:PFE
10.5
31%
0.3
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
Recce Pharmaceuticals Ltd
ASX:RCE
Average EV/EBIT: 2 011.9
Negative Multiple: -6
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
53
211%
0.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
675%
26.2
DK
Novo Nordisk A/S
CSE:NOVO B
28.5
83%
0.3
US
Johnson & Johnson
NYSE:JNJ
15.1
28%
0.5
US
Merck & Co Inc
NYSE:MRK
12.6
675%
0
CH
Roche Holding AG
SIX:ROG
11.9
28%
0.4
UK
AstraZeneca PLC
LSE:AZN
254.2
131%
1.9
CH
Novartis AG
SIX:NOVN
13.3
58%
0.2
US
Pfizer Inc
NYSE:PFE
15.9
68%
0.2

See Also

Discover More
Back to Top